Background and Study Aims Perioperative use of anticoagulant and platelet-inhibiting agents by patients undergoing spine surgery poses the dilemma of increased risk of hemorrhage. We examined the standards of use for these medications and expert opinions through a nationwide survey. Materials and Methods An online-based survey was conducted by invitation. A personal token to access the survey was sent to one representative of each neurosurgical and orthopaedic unit performing spine surgery and to all other active members of the Swiss Society of Neurosurgery and the Swiss Society of Spinal Surgery. A total of 97 e-mail invitations were sent to 19 representatives of neurosurgical or orthopaedic units and 78 registered neurosurgeons and orthopaedic surgeons who potentially perform spine surgery.
Introduction
Perioperative use of anticoagulant and platelet-inhibiting agents by patients undergoing spine surgery poses the dilemma of increased risk of hemorrhage as opposed to an increased risk of thrombosis or complications by discontinuing patients' anticoagulant or platelet-inhibiting medications. The management of perioperative anticoagulant and platelet-inhibiting agents for patients undergoing spine surgery is a widely discussed topic. Studies have discussed the controversial topic of increased risk of perioperative hemorrhage in patients undergoing treatment with platelet-inhibiting agents or low-molecular-weight heparin (LMWH). The incidence of perioperative hemorrhage reportedly ranges from 0.1% to 1%.
1,2 The study of the risk factors of perioperative hemorrhage is difficult because of the rarity of this complication, thereby leading to contradictory results. Although some studies report no risk of perioperative hemorrhage with the use of platelet-inhibiting agents or LMWH, 1,3-7 others indicate a risk.
8-10
Another controversial topic in the literature pertains to the use of LMWH to prevent venous thromboembolic diseases after spinal surgery. The incidence of deep vein thrombosis (DVT) in spinal surgery patients is reported to be 0.3 to 31%, depending on the patient population and the method of surveillance, and it has been reported to be considerably lower than that for patients undergoing major lower extremity surgery. 11, 12 Therefore, some studies have reported no need for postoperative LMWH after spinal surgery. 13, 14 Others, however, have reported a decreased incidence of venous thromboembolism after spine surgery.
4,7,15
Survey questionnaires are an excellent tool for examining current trends and expert opinions. Previous survey studies of perioperative platelet inhibition or anticoagulation date back to at least 2012, and they were limited to thromboprophylaxis for spinal surgery, such as the studies by Glotzbecker et al and Bryson et al, 13, 16 and perioperative use of low-dose aspirin for spinal surgery, such as the study by Korinth et al. 17 None of these surveys covered the more recent issue of new oral anticoagulants for patients undergoing spinal surgery, therapeutic anticoagulation in general, or bridging anticoagulation. Many recent studies of anticoagulation and platelet inhibition in patients undergoing spinal surgery have been published and might have changed the practice of spinal surgeons.
2-10
Previous studies have yielded contradictory results, and the recommendations for perioperative management with anticoagulant and platelet-inhibiting agents for patients undergoing spine surgery are inconsistent. Therefore, the aim of this study was to examine the standards of use for these medications and expert opinions about the subject.
Material and Methods
An online survey was created using the open source survey tool LimeSurvey, v.2.05 þ . The questionnaire was composed of 20 questions in four groups covering surgeon experience with spine surgery, perioperative use of thrombosis prophylaxis for spinal surgery, and perioperative management with anticoagulation and platelet inhibition (Appendix A). The survey was translated into German and English and uploaded to http://spinesurvey.limequery.org. Access was provided by invitation through an e-mail with a tokenactivated link. The response values were stored separately from the list of respondents and Internet protocol addresses.
A was 17.5 AE 9.3 years for orthopaedic surgeons and 14.5 AE 9.7 years for neurosurgeons (15.6 AE 9.5 years overall). The mean number of spinal surgeries per year was 263 AE 118 (range: 100-500) for orthopaedic surgeons and 185 AE 107 (range: 10-500) for neurosurgeons (214 AE 116 overall; range: 10-500).
Thrombosis Prophylaxis
Twenty-two surgeons (55%) prescribed LMWH on the evening before surgery. There was no significant difference between neurosurgeons and orthopaedic surgeons (58% versus 50%, respectively; p ¼ 0.462). Twenty-nine respondents (73%) prescribed compression stockings as part of the postoperative routine for the prevention of thromboembolism after spinal surgery. Regarding specific medication for thrombosis prophylaxis, multiple answers were possible. Nadroparin (Fraxiparine; Aspen Pharma, Durban, South Africa) was prescribed by 20 (50%), enoxaparin (Clexane; Sanofi-Aventis, Paris, France) was prescribed by 18 (45%), rivaroxaban (Xarelto; Bayer Pharma, Berlin, Germany) was prescribed by 7 (18%), unfractionated heparin was prescribed by 4 (10%), and dalteparin (Fragmin; Pfizer, Pearl River, New York, United States) was prescribed by 3 respondents (8%).
Medical thrombosis prophylaxis was recommenced postoperatively for lumbar decompression or lumbar spondylodesis by 38 respondents (95%) and after cervical decompression by 33 (83%). Twenty-eight surgeons (70%) responded that medical thrombosis prophylaxis was started 6 hours after surgery or during the evening of the day of surgery, and 10 (25%) responded that it was started on the first postoperative day. LMWH was prescribed by 31 (82%); rivaroxaban was prescribed by 7 (18%). Five surgeons (13%) administered thrombosis prophylaxis until the patient was ambulatory, 29 (76%) administered it until discharge, 2 (5%) administered it until 1 week postdischarge, and 2 (5%) administered it > 1 week postdischarge. No significant differences were noted between neurosurgeons and orthopaedic surgeons regarding the thrombosis prophylaxis prescribed.
Platelet Inhibition
►Table 1 provides the data regarding the practice of preoperative discontinuation of platelet inhibition. Platelet inhibition was discontinued more often before surgeries of the cervical spine than before those of the lumbar spine. At the level of the lumbar spine, platelet inhibition was discontinued more often for multilevel surgeries or before spondylodesis than for single-level decompression or diskectomy. On average, platelet inhibition was resumed 4 AE 2.5 days postoperatively, and orthopaedic surgeons started platelet inhibition (acetylic acid or clopidogrel) significantly earlier than neurosurgeons (3 AE 3 days versus 4 AE 2 days postoperatively, respectively; p ¼ 0.013). 
Therapeutic Anticoagulation with Rivaroxaban
Data regarding the practice of preoperative discontinuation of rivaroxaban are displayed in ►Table 2. If rivaroxaban for atrial fibrillation was discontinued, then 11 surgeons (28%) always prescribed bridging anticoagulation therapy with LMWH, 12 (30%) never prescribed bridging anticoagulation therapy with LMWH, 13 (33%) made the decision after asking an internist, and 4 (10%) answered "other." In cases of DVT/ pulmonary embolism (PE) > 1 year before the planned spinal surgery, bridging anticoagulation medication to replace rivaroxaban was always prescribed by 15 surgeons (38%) and was never prescribed by 8 (20%); 15 (38%) always made the decision after asking an internist. Nine (22.5%) routinely ordered serum-anti-Xa activity preoperatively, 23 (57.5%) did not, 6 (15%) ordered it depending on the patient's renal function, and 2 (5%) chose the option "other."
Traditional Anticoagulation Therapy Using Vitamin K Antagonists
Most respondents paused vitamin K antagonists ((e.g., warfarin, Coumadin) after spinal surgery for 1 to 2 weeks. When vitamin K antagonists where administered for DVT/ PE > 1 year previously or for intermittent atrial fibrillation, 15 to 20% of the respondents did not bridge the anticoagulation therapy. ►Table 3 lists the detailed results regarding the question of whether respondents prescribe bridging anticoagulation therapy when oral anticoagulants are paused.
Discussion
The results of this study reveal the rather heterogeneous practice of perioperative use of anticoagulant and platelet- inhibiting medications among spine surgeons. Among the respondents, 55% prescribed prophylactic anticoagulation preoperatively; there was no significant difference between orthopaedic surgeons (50%) and neurosurgeons (58%). Bryson et al reported that 31% of orthopaedic surgeons and 73% of neurosurgeons routinely used LMWH. 16 The incidence of DVT is reported to be 0.3 to 31% for patients who undergo spinal surgery. 11, 12, 15 One reason for the wide range in the incidence of DVT is the method used to diagnose this condition. If diagnosed with ultrasonography, there is a high incidence of asymptomatic DVT, as reported by Yamaguchi et al. 12 The symptomatic incidence of DVT is reported to be $ 1 to 3%.
4,11,14,19
Cox et al reported consequent chemical thrombosis prophylaxis for all patients undergoing spine surgery without an increased risk of morbidity and a DVT rate of 1%. 4 In contrast, a large review could not support or refute the use of chemical thrombosis prophylaxis in addition to compression stockings. 11 Among our respondents, 95% prescribed chemical thrombosis prophylaxis postoperatively and 73% prescribed compression stockings as part of the postoperative routine for the prevention of thromboembolism after spinal surgery. No significant differences in the use of thrombosis prophylaxis between neurosurgeons and orthopaedic surgeons were found. Regarding the time to start thrombosis prophylaxis, Strom et al recommended starting thrombosis prophylaxis 24 to 36 hours postoperatively, with a very low hemorrhage risk. 7 In a survey by Glotzbecker et al, the average time to start thrombosis prophylaxis was 48 hours after surgery. 13 Among our respondents, 70% started thrombosis prophylaxis on the day of surgery. Only $ 1 of 5 respondents discontinued platelet inhibition with acetylic acid before elective lumbar herniated disk or stenosis. However, most of our respondents ceased clopidogrel preoperatively. Surprisingly, even for cervical hernia surgery, less than half would cease acetylic acid preoperatively. Park et al recommended that acetylic acid should be discontinued 7 days before surgery. 10 Similarly, in the survey study by Korinth et al published in 2006, most German neurosurgeons (95%) ceased low-dose aspirin before elective spine surgery, on average, 7 days preoperatively. 17 Cuellar et al showed no appreciable increase in bleeding-related complication rates for patients with cardiac stents undergoing spine surgery who continued using aspirin compared with inpatients who discontinued aspirin before surgery.
5
A 2016 study by Soleman et al demonstrated no increased risk of postoperative hemorrhage if acetylic acid was continued by patients who underwent noninstrumented extradural lumbar spinal surgery; they concluded that its continuation seemed safe and therefore should be recommended. 6 Another study similarly showed no increased risk of postoperative spinal bleeding, even in a subgroup who underwent double platelet inhibition with aspirin and clopidogrel. 3 These results might explain the much lower percentage of spinal surgeons who discontinued acetylic acid before elective spine surgery in the current study compared with the survey in Germany performed Note: Data are presented as n (%). 1 Nonrespondent for all items. p values for the difference between the neurosurgical and orthopaedic group.
10 years previously by Korinth et al. 17 If discontinued, orthopaedic surgeons reestablished platelet inhibition (aspirin or clopidogrel) $ 1 day earlier than neurosurgeons (p ¼ 0.013). Steinberg et al showed a higher rate of bleeding if bridging anticoagulation therapy was used during perioperative interruption of platelet inhibition treatment. 20 Regarding cessation of therapeutic anticoagulation with rivaroxaban, a similarly size group of respondents chose to always or never use bridging anticoagulation therapy. On average, respondents ceased therapeutic rivaroxaban slightly more than 3 days before surgery, in accordance with the manufacturer's recommendation. Orthopaedic surgeons ceased rivaroxaban earlier than neurosurgeons. Unlike therapeutic anticoagulation with rivaroxaban and platelet inhibition, therapeutic anticoagulation with vitamin K antagonists was stopped and replaced with bridging anticoagulation therapy by most orthopaedic surgeons and neurosurgeons. This was the case for patients with mechanical aortic valve, mechanical mitral valve, and DVT/PE within the past 6 months. If the reason for vitamin K antagonist use was DVT or PE > 1 year before or for atrial fibrillation, 23 to 28% would rather not prescribe bridging anticoagulation therapy, which was similar to the practice for platelet inhibitors. No difference was found for orthopaedic surgeons and neurosurgeons regarding the use of bridging anticoagulation therapy for ceased vitamin K antagonists.
Douketis et al reported no need for perioperative bridging therapy for interrupted therapeutic anticoagulation with warfarin for patients with atrial fibrillation.
8 They found that the arterial thromboembolic risk after cessation of therapeutic anticoagulation was equal to that when no bridging anticoagulation therapy was administered; however, the risk of hemorrhage was increased when bridging anticoagulation therapy was used. They also stated that the use of bridging anticoagulation therapy has been anchored to the premise that the associated higher bleeding risk was clinically acceptable because it would be offset by a lower risk of perioperative arterial thromboembolism.
8
The main limitation of the present study was the low response rate of invitees from private practices. However, the response rate by the unit representatives was excellent for an online-based survey. The overall response rate of 41% was slightly lower than that of other surveys among spine surgeons that reported response rates of 49 to 67.6%.
13,17
The survey was performed in only one country that might have limited the generalizability of the results. The responses were anonymized so the respondents' names and the response sets were stored in different files. Therefore, the differences between the units involved in spine surgery and surgeons in the private practice could not be established.
Direct evaluation of complications (hemorrhage/DVT/PE) related to different perioperative anticoagulation practices could not be performed through a survey. These complications have a very low incidence, and the long experience of the responding surgeons did not suggest that they would continue riskier practice if they experienced higher complication rates.
This survey study adds a comprehensive overview of current practice regarding the use of anticoagulant and platelet-inhibiting medications in the perioperative setting of elective spinal surgery. To date, it is the first survey among spinal surgeons regarding this subject in the past 5 years, and it is also the most comprehensive. In contrast to previous surveys, it included the use of platelet inhibition and anticoagulation.
Furthermore, it is the first survey examining current standards for the use of new oral anticoagulants-in this case, the most widely used example is rivaroxaban-and bridging anticoagulation therapy for spinal surgery. The results were similar to those of previous survey studies of heterogeneous practice with regard to perioperative use of anticoagulant and platelet-inhibiting medications for elective spinal surgery patients. However, they also demonstrated that newer results reported in the literature might have influenced the current practice in this field even those there is still very little evidence.
Conclusions
Administration and discontinuation of anticoagulant and platelet-inhibiting medications in the perioperative setting of spinal surgery differ vastly between different units and surgeons. Recommendations or a protocol from the National Spine Surgeon Society may be helpful to develop nationwide guidelines.
For the following spine surgery procedures, do you prescribe prophylactic low molecular heparin postoperatively?
After straightforward elective spine procedures, when do you begin prophylactic low molecular heparin?
Please choose only one of the following: 
Platelet-inhibiting medications
For the following spine surgery procedures, do you always discontinue acetylsalicylic acid used for platelet inhibition?
When discontinuing therapeutic dose Xarelto preoperatively in patients with history of DVT/PE (>1 year ago), do you use low molecular heparin as a temporary replacement?
Please choose only one of the following:
Always consulting an internist • Other
For how long after the following spinal procedures do you discontinue oral anticoagulants (Marcoumar, warfarin)?
In the following cases, do you use heparin while discontinuing Vitamin K antagonists perioperatively?
Please choose the appropriate response for each item: Perioperative Anticoagulant and Platelet-inhibiting Medications Baschera et al. 407
